RE: RNS4 Jun 2019 10:20
Perrins
Here is your answer
Oxford, UK - 29 May 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announces that, further to the announcement of 28 May in relation to Novo Holdings' agreement to subscribe for 6,568,024 new ordinary shares in OXB (the "Subscription Shares") at a price of £6.90 per share (the "Subscription Price"), Novo Holdings has now exercised in full its option under the Subscription Agreement to subscribe to a further 1,181,976 new ordinary shares (the "Further Shares") in OXB at the Subscription Price (the "Subscription Option"). Exercise of the Subscription Option will increase Novo Holdings' ownership to 10.1% of OXB.